Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Indaptus Therapeutics ( (INDP) ) has provided an announcement.
On June 12, 2025, Indaptus Therapeutics announced the completion of a private placement, raising $2.3 million through convertible promissory notes and warrants. The funds will be used for research and development, including a Phase 1b/2 clinical trial, and general corporate purposes. This move is part of an ongoing effort to raise up to $5 million, enhancing the company’s financial position and supporting its clinical initiatives.
The most recent analyst rating on (INDP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections.
Average Trading Volume: 721,155
Technical Sentiment Signal: Sell
Current Market Cap: $5.53M
See more data about INDP stock on TipRanks’ Stock Analysis page.